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The genetic diversity of loci implicated in glucocorticoid (GC) response has been associated with interindi-
vidual variations in responsiveness to GC in various diseases, such as asthma and inﬂammatory bowel dis-
orders. In acute graft-versus-host disease (aGVHD), similar differences of ﬁrst-line therapy responsiveness are
also observed, with approximately 40% of patients failing to respond to GC. Here, the distribution of func-
tionally relevant single nucleotide polymorphisms (SNP) belonging to the GC-induced transcript 1 GLCCI1
(rs37972) and the glucocorticoid receptor (rs41423247, rs6195 and rs6198) gene loci were analyzed alongside
clinical factors for their association with the response to corticosteroids in aGVHD. The frequencies of variant
alleles did not differ signiﬁcantly between corticoresistant patients, their donors, and their corticosensitive
peers (P ¼ .10 to 1.00). Severe and early onset of aGVHD, bone marrow as the stem cell source, and an HLA
mismatch were associated with the failure to respond to GC in logistic regression. After including the single
SNPs to the model, carriers of the rs41423247 polymorphism had a higher probability of responding to GC,
whereas all other polymorphisms did not affect the likelihood of response.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION and infections, but also genetically driven vulnerability may
The curative potential of allogeneic hematopoietic stem
cell transplantation (HSCT) for many hematologic disorders
is signiﬁcantly curtailed by the complications it occasions [1].
In particular, graft-versus-host disease (GVHD) will affect at
the most 70% of subjects, of which approximately one-half
will not respond to ﬁrst-line treatment with glucocorti-
coids (GC). Steroid-refractory GVHD (SR-GVHD) has a
particularly poor prognosis, with reported long-term sur-
vival rates between 10% and 30% [2]. The question of why
some patients respond and others do not can be approached
from different angles. Not only clinical characteristics, such
as previous and/or concurrent treatment regimen, donor/
recipient sex constellation, the interaction between GVHDedgments on page 1250.
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ty for Blood and Marrow Transplantation.predispose an individual to treatment refractoriness [3-5].
GC resistance can be observed in various pathological
settings, presumably arising from pharmacokinetic or phar-
macogenetic variants in patients [6]. Tantisira et al. identiﬁed
a signiﬁcant correlation between a functional single nucle-
otide polymorphism (SNP) in the GLCCI1 gene and the clin-
ical phenotype of resistance to steroid treatment of asthma
[7]. Further advances on determinants of GC response were
the ﬁndings of GC sensitivity modulation through poly-
morphisms of the glucocorticoid receptor (GR) gene, eg, at
the BclI restriction fragment length, at codon N363 of exon 2
or in exon 9b [8,9]. We sought to determine if a correlation
between previously described GC responsee
modifying SNPs and the clinical phenotype of response to
acute GVHD (aGVHD) treatment with GC can be found.
PATIENTS AND METHODS
Patient Selection
In a previous study involving patients with SR-GVHD [10], we reported
similar results of second-line therapy using either mycophenolate mofetil,
inolimomab, or etanercept. The patients enrolled at this time (n ¼ 64) were
Figure 1. Overall survival after the time of diagnosis of aGVHD.
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macogenetic variants associated with steroid resistance in patients
demonstrating GC refractoriness in other diseases, such as asthma [7]. As a
control, a cohort of 80 patients with steroid-sensitive GVHD was analyzed
for the same polymorphisms.
Study Design and Statistical Analyses
Patients gave their consent to the evaluation of the data and received
treatment on a local ethical committeeeapproved research protocol
(reference BIOGVH 14650). Patients having received cord blood trans-
plantation were not included in this analysis. aGVHD was suspected at the
appearance of the following symptoms after transplantation: erythema/
exanthema, diarrhea, nausea, emesis, abdominal pain, anorexia, or chole-
static hepatitis. Glucksberg and consensus criteria determined the diagnosis,
staging, and grading of GVHD [11,12]. SR-GVHD was deﬁned as either the
absence of remission by 14 days, stable disease by 7 days, or progression
within 3 days after the beginning of corticosteroid treatment at a dose of 1 to
2 mg/kg/day. Corticoresistant patients were treated in second-line in an
interventional trial evaluating treatment of SR-GVHD with mycophenolate
mofetil, inolimomab, or etanercept [10].
The choice of SNPs for the analysis was based on their established
functional impact and their previously demonstrated association with GC-
related treatment response. Genomic DNA was extracted from EDTA-
treated peripheral blood samples using a standard salting-out method to
be subjected to routine HLA typing and then stored frozen until the present
study. All participants were genotyped for functional polymorphisms in
GLCCI1 (rs37972 C–>T) and GR (in the BclI restriction fragment length:
rs41423247 G–>C, as a point mutation in exon 2 NS363: rs6195 A–>G or in
exon 9b: rs6198 A–>G). The genotyping was performed by a TaqMan 50-
nuclease assay (Applied Biosystems, Foster City, CA) with allele-speciﬁc
ﬂuorogenic oligonucleotide probes using pre-developed TaqMan assay
genotyping kits (Applied Biosystems).
The frequencies of GLCCI1 and GR polymorphisms were assessed in
patients affected by aGVHD and in their donors and compared according to
their response to GC. Variables were compiled and compared using tests for
categorical or continuous data. Differences in genotype distribution in pa-
tients and donors were tested using contingency tables and compared using
Pearson’s chi-squared and Fischer’s exact test, where appropriate. For the
SNP data, in departure from Hardy-Weinberg equilibrium, statistical ana-
lyses involved Cochran-Armitage trend testing on the basis of the genotypes.
Factors possibly inﬂuencing the response to GC, such as patient age, donor/
host combinations for gender and HLA mismatch, stem cell source, grade
and acuteness of aGVHD onset, as well as the SNPs, were ﬁrst tested by
means of univariate analysis. Adding each covariable subsequently to for-
ward conditional logistic regression, we then examined the signiﬁcance of
clinical predictors of response to corticosteroid treatment as well as that of
the studied polymorphisms. Overall survival was estimated by Kaplan-
Meier analysis. All tests were 2-sided and P values  .05 were considered
signiﬁcant. Statistical analyses were performed on SPSS version 19 (SPSS Inc,
Chicago, IL), GraphPad Prism 5.0a (GraphPad Software, San Diego, CA), and
Stata/SE 12.1 (StataCorp LP, College Station, TX).
RESULTS
Patient, Transplantation, and Disease Characteristics
One hundred forty-four patients (57 female, 87 male)
ages 5 to 66 years (median, 44 years) presenting cortico-
sensitive (CS) or corticorefractory aGVHD after allogeneic
HSCT (between 1999 and 2013) were identiﬁed for this
analysis. Stem cell source at ﬁrst transplantation was bone
marrow in 38 (26%) and mobilized peripheral blood stem
cells in 106 (74%). Stem cell donors were identical siblings
(n ¼ 63, 44%), matched unrelated donors (n ¼ 60, 42%), or
mismatched unrelated donor (n ¼ 21, 14%). Median follow-
up from HSCT was 19.5 months (range, 1 to 141).
aGVHD arose at a median time of 20 days after HSCT.
GVHD grades were 4 in 24 (17%), 3 in 42 (29%), 2 in 63 (44%),
and 1 in 15 patients (10%). Sixty-four patients qualiﬁed as
being SR, as deﬁned above, and received second-line
immunosuppression, consisting either of MMF in 27 pa-
tients who had not previously received this substance in
prophylaxis (42% of the patients with SR-GVHD), inolimo-
mab in 18 (28%), and etanercept in 19 patients (30%). Second-
line treatment began at a median of 13 days after the diag-
nosis of GVHD. Eighty-three patients developed chronicGVHD. Kaplan-Meier estimated overall survival at 5 years
after the time of diagnosis of acute GVHD was signiﬁcantly
lower for patients affected by SR-GVHD than for the patients
who responded to corticosteroids (23%  5% standard error
versus 75%  5%; log-rank P < .0001) (Figure 1).
As previously described byWestin et al. [5], severe (grade
3 or 4) GVHD occurring early in the course, ie, within 14 days
of HSCT, resulted in the strongest risk of failure to respond to
corticosteroids (odds ratio [OR],18.1; 95% conﬁdence interval
[CI], 6.46 to 50.73; P < .0001) on univariate analysis. Further
predictors of the failure of aGVHD to respond to GC were, in
decreasing order of importance, the following: bone marrow
stem cell source (OR, 3.88; 95% CI, 1.76 to 8.55; P¼ .001), HLA
mismatch (OR, 5; 95% CI, 1.72 to 14.54; P ¼ .002), myeloa-
blative conditioning (OR, 2.89; 95% CI, 1.47 to 5.72; P ¼ .002),
and sex mismatch in the direction of a female donor to male
recipient (OR, 2.4; 95% CI, 1.14 to 5.06; P ¼ .02). There was a
trend for higher response rates to corticosteroids in patients
receiving antithymoglobulin (ATG) before transplantation
(OR, 0.54; 95% CI, .27 to 1.11; P¼ .09), whichwas independent
of the stem cell source (bone marrow versus peripheral
blood stem cell source; P ¼ .13). Patient and transplantation
characteristics are detailed in Table 1.
GLCCI1 and GR variant frequencies in patients with SR-GVHD
and CS-GVHD
The GLCCI1 rs37972 T variant allele did not occur more
frequently either in patients with CS- or SR-GVHD (OR, 1.00;
95% CI, .62 to 1.62; P ¼ 1.00). The frequency of the T allele in
donors to patients with CS-GVHD was higher than in the
donors to patients who developed SR-GVHD, albeit not
reaching the level of statistical signiﬁcance (58 of 150 alleles
in the donors of patients with CS-GVHD versus 41 of 118
alleles in the donors of patients with SR-GVHD; OR, .85; 95%
CI, .51 to 1.40; P ¼ .51) (Table 2, Figure 2).
In terms of GR polymorphism, we found that the fre-
quency of the BclI rs41423247 C allele was higher in patients
with CS-GVHD than in those with SR-GVHD (63 of 158 [40%]
versus 42 of 128 [33%] alleles; OR, .74; 95% CI, .45 to 1.20; P ¼
.22 in CS-GVHD and SR-GVHD, respectively). As for the po-
tential inﬂuence of the donor BclI rs41423247 C allele, we
observed 47 of 150 variant alleles in donors to patients who
later developed CS-GVHD and 41 of 118 in donors to patients
with SR-GVHD (OR, 1.17; 95% CI, .69 to 1.95; P ¼ .56) (Table 2,
Figure 2). Concerning the NS363 rs6195, we found that the
G allele was equally distributed in the 2 patient groups (OR,
Table 1
Patient, Transplantation, and GVHD Characteristics
Variables CS-GVHD SR-GVHD P Value
n 80 64
Age, median (range), yr 48 (15-66) 37.5 (5-64) .01
Gender, male/female 47(59)/33(41) 40(63)/24(37) .65
Diagnosis
Acute lymphoblastic/
myelogenous
leukemia
26 (32) 33 (52) .10
Myelodysplastic/
myeloproliferative
neoplasia
20 (25) 10 (16)
Lymphoid neoplasia* 27 (34) 13 (20)
Aplastic anemia 7 (9) 8 (13)
Transplant cell source
Bone marrow 12 (15) 26 (41) .001
Peripheral blood 68 (85) 38 (59)
Conditioning
Reduced intensity 52 (65) 25 (39) .002
Myeloablative 28 (35) 39 (61)
ATG
No 48 (60) 47 (73) .09
Yes 32 (40) 17 (27)
GVHD prophylaxis
CsA/MTX 28 (35) 35 (55) .16
CsA/MMF 49 (61) 20 (31)
CsA 3 (4) 9 (14)
Donor type
Identical sibling 45 (56) 18 (28) <.001
Matched unrelated 30 (38) 30 (47)
Mismatched unrelated 5 (6) 16 (25)
CsA indicates cyclosporine; MTX, methotrexate; MMF, mycophenolate
mofetil.
Data presented are n (%), unless otherwise indicated.
* Lymphoid neoplasia includes Hodgkin and non-Hodgkin lymphoma,
chronic lymphocytic leukemia, plasma cell neoplasia.
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amongst donors. Finally, the GR exon 9b rs6198 G allele was
found at a higher frequency in patients with CS-GVHD (OR,
.74; 95% CI, .39 to 1.43; P ¼ .38) and at a higher frequency in
the donors to patients with CS-GVHD compared with the
donors to patients with SR-GVHD, although the difference inTable 2
GR and GLCCI1 Polymorphisms in Patients Affected by CS- and SR-GVHD and
their Respective Donors
Variables CS-GVHD
Patients
SR-GVHD
Patients
CS-GVHD
Donors
SR-GVHD
Donors
rs37972 Allele
frequency
C 100 (63) 81 (63) 92 (61) 77 (65)
T 58 (37) 47 (37) 58 (39) 41 (35)
P 1.00 .51
rs41423247 Allele
frequency
G 95 (60) 86 (67) 103 (69) 77 (65)
C 63 (40) 42 (33) 47 (31) 41 (35)
P .22 .56
rs6195 Genotype
frequency
AA 74 (94) 61 (95) 75 (100) 59 (100)
AG 5 (6) 2 (3) 0 0
GG 0 1 (2) 0 0
P .98 n.a.
Rs6198 Allele
frequency
A 131 (83) 111 (87) 121 (81) 104 (88)
G 27 (17) 17 (13) 29 (19) 14 (12)
P .38 .10
N.A. indicates not available.frequencies did not reach the level of statistical signiﬁcance
(OR, .56; 95% CI, .28 to 1.11; P ¼ .10) (Table 2, Figure 2).
rs37972, rs41423247 and rs6198 were in Hardy-Weinberg
equilibrium, whereas the rs6195 was not.
Association between clinical characteristics, gene
polymorphisms and the response to GC
The clinical factors that resulted in a signiﬁcant effect on
univariate analysis were retained for logistic regression, ie,
hyperacute severe GVHD, stem cell source, conditioning
regimen intensity, HLA mismatch, and sex mismatch, a
model to which the individual SNPs were included. As in
univariate analysis, patients who had a severe and hyper
acute manifestation of GVHD had a signiﬁcantly higher risk
of not responding to GC than the patients who either
developed early but mild aGVHD or severe aGVHD beyond
the ﬁrst 14 days after transplantation (n ¼ 40, P < .0001).
Further factors associated with nonresponse to steroid
therapy were bone marrow as the cell source of HSCT (n ¼
38, P ¼ .001) and an HLA mismatch (n ¼ 21, P ¼ .019). The
clinical factors of a myeloablative conditioning (n ¼ 67, P ¼
.61) and sex mismatch in the direction of a female donor to a
male patient (n ¼ 40, P ¼ .33) did not prove to be signiﬁcant
in logistic regression.
The effects of the individual SNPs in donors and patients
in forward conditional logistic regression were nonsigniﬁ-
cant for the following SNP in donors and recipients: rs6195
SNP-positive recipient (n ¼ 8, P ¼ .97), rs6198 SNP-positive
donor (n ¼ 36, P ¼ .15), rs6198 SNP-positive recipient (n ¼
40, P¼ .83), rs37972 SNP-positive donor (n¼ 77, P¼ .50), and
rs37972 SNP-positive recipient (n ¼ 83, P ¼ .92). The asso-
ciation between the presence of the SNP rs41423247 and a
response to GC was signiﬁcant in the recipient (n ¼ 88, P ¼
.009) but not in the donor (n¼ 73, P¼ .12) (results detailed in
Table 3).
DISCUSSION
The development of GVHD seriously diminishes the
curative potential of allogeneic HSCT. Around one half of
allogeneic HSCT recipients will develop this complication, of
which between 40% and 60% will respond to standard
treatment with GC [13]. For the patients who do not
respond, a second-line treatment is often initiated, however,
at the price of even lower response rates and a higher in-
fectious burden, and ultimately resulting in a very poor
prognosis [14].
The mechanisms of action of GC are primarily that of
inducing lymphocyte apoptosis and increasing the tran-
scription of anti-inﬂammatory cytokines while decreasing
the transcription of their proinﬂammatory counterparts
[15,16]. In the context of aGVHD, GC has further been found
to suppress CD8-positive T cells [17]. Our understanding of
GC resistance mainly derives from research conducted in the
ﬁeld of chronic inﬂammatory diseases and, in particular,
asthma. Aside from pharmacokinetic interferences, such as
suboptimal drug absorption or distribution, various molec-
ular mechanisms have been identiﬁed, such as an increased
drug efﬂux, eg, under the control of multidrug resistance
transporter pump SNPs [18], defective binding, or failure of
the GR to translocate to the nucleus due to post-translational
alterations or through competition [19,20]. In addition,
interindividual differences in the response to corticosteroids
have been ascribed to genetic variants of GLCCI1 and GR [7,8].
Previous studies have suggested lower response rates to
GC in patients experiencing higher initial GVHD stages [21],
Figure 2. Allele frequencies in patients and donors.
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pairs [4], and in case of HLA disparities between donors
and recipients [22]. Our ﬁndings replicate the negative effect
of severe and early onset of GVHD, as well as the effect of a
mismatched donor. Further, a detrimental effect of bone
marrow as the stem cell source was observed in this study.
With the addition of ATG to GVHD prophylaxis, acute and
chronic GVHD incidences can be signiﬁcantly decreased [23].
Interestingly, should aGVHD occur after an ATG-containing
regimen, a trend to higher response rates to GC could be
observed in our data.
The following most common SNPs involving a modiﬁed
response to GC were screened for their association with the
response to GC in aGVHD: rs37972, rs41423247, rs6195, and
rs6198. Patients with asthma carrying mutant alleles at
rs37972 and rs37973 of the GLCCI1 gene (both SNPs being in
complete linkage disequilibrium) were found to be more
likely to have an inferior response to GC treatment of asthma
[7]. In our study, rs37972 SNP-positive donors and recipients
were neither increased nor were more likely to have SR-
GVHD.
Unlike previous reports of an association between rs6195
variants and GC resistance [24], an identical frequency of the
G allele in the donors and patients of both groups was found
in our study. The rs6198 G allele has been implicated in
reduced responsiveness to GC in patients [8,25]. Although an
increased number of mutant alleles was noted in the donors
to patients with CS-GVHD, logistic regression did not support
an association between this variant and a particular clinical
phenotype of GC responsiveness. The rs6195 was not in
Hardy-Weinberg equilibrium. After having excluded geno-
typing errors, departure from Hardy-Weinberg equilibrium
can be explained either by chance, particularly in a small set
of cases or by a genuine genetic association with the devel-
opment of a disease [26]. The focus of our study on patients
with aGVHD implied a patient selection within the collective
of all HSCT recipients. Thus, departure from Hardy-Weinberg
equilibrium could also indirectly indicate a genetic GCTable 3
Odds Ratios of Failure to Respond to GC Therapy of aGVHD in Logistic
Regression
Predictor n OR 95% CI P Value
Hyperacute severe aGVHD 40 34.50 10.15-117.22 <.0001
BM 38 5.76 2.07-16.03 .001
HLA mismatch 21 4.49 1.29-15.64 .019
Recipient rs41423247 carrier 88 0.28 .11-0.72 .009
BM indicates bone marrow.homeostasis background to the development of GVHD.
Finally, individuals carrying the Bcl1 C allele (rs41423247)
have been reported to have a constitutionally determined
higher sensitivity to GC [27,28]. Although the enhanced
sensitivity to GC due to this SNP has been demonstrated as
cited in autoimmune disorders, knowledge of the underlying
mechanism of action is limited. Patients who responded to
GC had higher frequencies of the C allele and an association
between this allele and a lower risk of developing SR-GVHD
was seen in logistic regression.
In a recent study by Theiss-Suennemann et al. in a
murine model, when recipients received allogeneic T cells
lacking GR expression, aGVHD had a far more severe course
than in controls [17]. This ﬁnding suggests an important
role of donor T cells in the response to GC, although we
have detected an effect on the determination of response
in the genetic background of the recipient. Several factors
may explain this discrepancy; foremost, the different
subjects studied. On account of the differences in donor,
host, and transplantation characteristics in mice and
humans (ie, different conditioning regimens, cell sources,
genetic and immunological matches, host microbiome, and
age), the results of murine models cannot be fully aligned
with the results in humans [29]. Moreover, further cell sets,
eg, host antigen-presenting cells, cytokine modulation, and
also tissue response to GC play a role in the complex
interplay of host and donor immunity in human aGVHD
[30-32]. Our ﬁndings warrant further validation of the
genetic determinants of response to GC in donor and
recipient pairs both in functional assays and in a larger
cohort.
In conclusion, the SNP rs41423247 can be linked to the
response to treatment with GC in patients who have expe-
rienced aGVHD. Other SNPs may play response-modifying
roles in the treatment of aGVHD with GC, by way of
example other genetic variants either on the GR gene,
possibly in linkage disequilibrium to the rs41423247, or
encoded on other genes (eg, multiple drug resistance). Our
data suggest that the severity of presentation of aGVHD,
donor-recipient disparities, and the transplantation source
can inﬂuence, at least partly, the response to GC. Our ﬁndings
provide new insights on constitutional GC respon-
seemodulating variants in aGVHD and should they be
further validated, could contribute to the management of
immunosuppressive treatment of aGVHD. Wider in-
vestigations of the genome and functional assays would
allow a more comprehensive understanding of the pharma-
cogenetics behind the treatment of aGVHD.
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